Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

Abstract TNB‐383B is a fully human BCMA‐targeting T‐cell engaging bispecific monoclonal antibody (T‐BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients with relapsed multiple myeloma (MM). BMMC were treated ex...

Popoln opis

Bibliografske podrobnosti

Principais autores:	David M. Foureau, Manisha Bhutani, Myra Robinson, Fei Guo, Duy Pham, Ben Buelow, Nury Steuerwald, Katherine Rigby, Elise Tjaden, Marina Leonidas, Barry A. Paul, Shebli Atrash, Ami Ndiaye, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2020-07-01
Serija:	eJHaem
Teme:	antibody therapy immunophenotyping myeloma
Online dostop:	https://doi.org/10.1002/jha2.69
Oznake:	Označite Brez oznak, prvi označite!